Raymond James: ''If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka'
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $78.00 price target on Vera Therapeutics (NASDAQ: VERA)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)